China Meheco Group (SHA:600056) received a drug registration certificate for tedisamil phosphate tablets from the Chinese drug administration, according to a Shanghai bourse disclosure on Thursday.
The drug is primarily used for the treatment of acute bacterial skin and skin structure infections.
The pharmaceutical company invested approximately 16.4 million yuan into the research and development of the project, the disclosure said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.